📊 DOCS Key Takeaways
Is DOCS a Good Investment? Thesis Analysis
Doximity demonstrates exceptional financial health with industry-leading profitability metrics (89.8% gross margin, 35.4% net margin) and strong growth (20% revenue YoY, 51.2% net income YoY). The company generates substantial free cash flow ($216.9M, 43.4% FCF margin) with zero debt and fortress-like balance sheet strength (6.63x current ratio), positioning it as a highly efficient, cash-generative business with substantial reinvestment capacity.
Why Buy DOCS? Key Strengths
- Exceptional profitability: 89.8% gross margin and 35.4% net margin indicate strong pricing power and operational efficiency
- Accelerating earnings: 51.2% YoY net income growth substantially outpaces 20% revenue growth, demonstrating operating leverage
- Fortress balance sheet: $979.3M equity, zero debt, $64.8M cash, and 6.63x current ratio provide strategic flexibility
- High-quality revenue growth: 20% YoY revenue growth in software/services segment with improving unit economics
- Exceptional cash generation: $216.9M operating cash flow (43.4% FCF margin) with zero capex intensity
- Strong capital efficiency: 18.1% ROE and 15.3% ROA demonstrate superior asset utilization
DOCS Investment Risks to Consider
- Concentration risk: Heavy dependence on physician network and healthcare sector cyclicality could impact growth
- Margin sustainability: Exceptional net margins (35.4%) may face pressure from increased competition or margin normalization
- Low debt capacity: While zero debt is conservative, lack of financial leverage may indicate underutilization of capital structure
- Market saturation: Penetration of US physician market may eventually limit organic growth acceleration rates
- Regulatory risk: Healthcare sector exposure creates ongoing compliance and regulatory compliance burden
Key Metrics to Watch
- Revenue growth rate sustainability and year-over-year trend deceleration/acceleration
- Operating margin progression and gross margin stability amid competitive pressures
- Free cash flow conversion rate and capital allocation decisions (buybacks, M&A, or dividends)
- Customer retention rates and new customer acquisition trends in core physician platform
- Net income growth rate relative to revenue growth and operating leverage sustainability
DOCS Financial Metrics
💡 AI Analyst Insight
The 43.4% free cash flow margin provides substantial flexibility for dividends, buybacks, and strategic investments. Strong liquidity with a 6.63x current ratio provides a solid financial cushion.
DOCS Profitability Ratios
DOCS vs Technology Sector
How Doximity, Inc. compares to Technology sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is DOCS Overvalued or Undervalued?
Based on fundamental analysis, Doximity, Inc. appears fundamentally strong relative to the Technology sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
DOCS Balance Sheet & Liquidity
DOCS 5-Year Financial Trend & Growth Analysis
5-Year Trend Summary: Doximity, Inc.'s revenue has grown significantly by 66% over the 5-year period, indicating strong business expansion. The most recent EPS of $0.53 reflects profitable operations.
DOCS Growth Metrics (YoY)
DOCS Quarterly Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2026 | $168.6M | $61.6M | $0.31 |
| Q2 2026 | $136.8M | $44.2M | $0.22 |
| Q1 2026 | $126.7M | $41.4M | $0.21 |
| Q3 2025 | $135.3M | $48.0M | $0.24 |
| Q2 2025 | $113.6M | $30.6M | $0.15 |
| Q1 2025 | $108.5M | $28.4M | $0.13 |
| Q3 2024 | $115.3M | $33.5M | $0.16 |
| Q2 2024 | $102.2M | $26.3M | $0.12 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
DOCS Capital Allocation
DOCS SEC 10-K & 10-Q Filing Analysis
Access official SEC EDGAR filings for Doximity, Inc. (CIK: 0001516513)
📋 Recent SEC Filings
| Date | Form | Document | Action |
|---|---|---|---|
| Mar 12, 2026 | 4 | xslF345X05/wk-form4_1773363596.xml | View → |
| Mar 12, 2026 | 4 | xslF345X05/wk-form4_1773363529.xml | View → |
| Mar 5, 2026 | 4 | xslF345X05/wk-form4_1772745781.xml | View → |
| Feb 18, 2026 | 4 | xslF345X05/wk-form4_1771469673.xml | View → |
| Feb 18, 2026 | 4 | xslF345X05/wk-form4_1771469603.xml | View → |
❓ Frequently Asked Questions about DOCS
What is the AI rating for DOCS?
Doximity, Inc. (DOCS) has an AI rating of STRONG BUY with 88% confidence, based on fundamental analysis of SEC EDGAR filings.
What are DOCS's key strengths?
Claude: Exceptional profitability: 89.8% gross margin and 35.4% net margin indicate strong pricing power and operational efficiency. Accelerating earnings: 51.2% YoY net income growth substantially outpaces 20% revenue growth, demonstrating operating leverage.
What are the risks of investing in DOCS?
Claude: Concentration risk: Heavy dependence on physician network and healthcare sector cyclicality could impact growth. Margin sustainability: Exceptional net margins (35.4%) may face pressure from increased competition or margin normalization.
What is DOCS's revenue and growth?
Doximity, Inc. reported revenue of $499.5M.
Does DOCS pay dividends?
Doximity, Inc. does not currently pay dividends.
Where can I find DOCS SEC filings?
Official SEC filings for Doximity, Inc. (CIK: 0001516513) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is DOCS's EPS?
Doximity, Inc. has a diluted EPS of $0.88.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is DOCS a good stock to buy right now?
Based on our AI fundamental analysis in March 2026, Doximity, Inc. has a STRONG BUY rating with 88% confidence. The AI analysis suggests favorable fundamentals based on SEC filings. This is not investment advice.
Is DOCS stock overvalued or undervalued?
Valuation metrics for DOCS: ROE of 18.1% (sector avg: 22%), net margin of 35.4% (sector avg: 18%). Compare these metrics with sector averages to assess valuation.
Should I buy DOCS stock in 2026?
Our dual AI analysis gives Doximity, Inc. a combined STRONG BUY rating for 2026. Revenue is data pending, with profitability above sector average. Always conduct your own research.
What is DOCS's free cash flow?
Doximity, Inc.'s operating cash flow is $216.9M, with capital expenditures of $0.0. FCF margin is 43.4%.
How does DOCS compare to other Technology stocks?
Vs Technology sector averages: Net margin 35.4% (avg: 18%), ROE 18.1% (avg: 22%), current ratio 6.63 (avg: 2.5).